Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Taking Aggressive Approach To Cardiovascular Development

Executive Summary

Despite several setbacks this year, and a major competitor's withdrawal from further R&D in the field, Merck reiterated its commitment to cardiovascular R&D at its annual business review Dec. 9 and outlined an aggressive cardiovascular development program

Related Content

Vorapaxar Woes Increase Pressure On Remainder Of Merck CV Pipeline
Merck’s Anacetrapib Debut Many Years Away, Despite Robust Phase III Data
Chart: Merck's Major CV Trials
Pipeline Integration Leaves Merck's Backbone As Cardiovascular, Infectious Disease
American Heart Association Scientific Sessions, In Brief
Resverlogix Thinks RVX-208 Can Succeed At Reducing Arterial Plaque Where Pfizer's Torcetrapib Failed
Merck/Schering: The Next Wave Of Consolidation
Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo
Merck's Cordaptive: Just Another Cholesterol Combo, or More?
Merck's Cordaptive: Just Another Cholesterol Combo, or More?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts